August 14, 2018

Joseph J. Ferra, Jr.
Chief Financial Officer
Syros Pharmaceuticals, Inc.
6200 Memorial Drive, Suite 300
Cambridge, MA 02139

       Re: Syros Pharmaceuticals, Inc.
           Form 10-K for the fiscal year ended December 31, 2017
           Filed March 12, 2018
           Form 10-Q for the quarterly period ended June 30. 2018
           Filed August 7, 2018
           File No. 001-37813

Dear Mr. Ferra:

       We have reviewed your filing and have the following comments. In some of
our
comments, we may ask you to provide us with information so we may better
understand your
disclosure.

       Please respond to these comments within ten business days by providing
the requested
information or advise us as soon as possible when you will respond. If you do
not believe our
comments apply to your facts and circumstances, please tell us why in your
response.

     After reviewing your response and any amendment you may file in response
to these
comments, we may have additional comments.

Form 10-K for the fiscal year ended December 31, 2017

Item 9A. Controls and Procedures
Internal Control Over Financial Reporting, page 139

1.    You disclose that you have not included a report of management's
assessment regarding
      internal control over financial reporting or an attestation report of the
company's
      registered public accounting firm due to a transition period established
by rules of the
      SEC for newly public companies. Please note that although you are not
required to have
      an attestation report done by your independent public accounting firm,
you are required to
      include a report of management's assessment regarding internal control
over financial
 Joseph J. Ferra, Jr.
Syros Pharmaceuticals, Inc.
August 14, 2018
Page 2
         reporting in your Form 10-K due to the passage of time since your
initial registration
         statement and the number of Form 10-Ks filed since that initial
registration statement.
         Please revise by amending your Form 10-K for the year ended December
31, 2017 to
         include this report as required by Item 308 of Regulation S-K.
Form 10-Q for the quarterly period ended June 30. 2018

Item 6. Exhibits, page 32

2.       Please amend your filing to provide new certifications filed as
Exhibits 31.1 and 31.2 to
         conform exactly to that provided in Item 601(b)(31) of Regulation S-K
as it relates
         to internal controls over financial reporting (ICFR). In this regard,
the introductory
         sentence in paragraph 4 should refer to ICFR as defined in the
Exchange Act and
         certification 4(b) should discuss your obligations related to ICFR.
        We remind you that the company and its management are responsible for
the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action
or absence of
action by the staff.

        You may contact Vanessa Robertson at 202-551-3649 or Kevin Vaughn at
202-551-
3494 if you have any questions.



FirstName LastNameJoseph J. Ferra, Jr.                        Sincerely,
Comapany NameSyros Pharmaceuticals, Inc.
                                                              Division of
Corporation Finance
August 14, 2018 Page 2                                        Office of
Healthcare & Insurance
FirstName LastName